ArticleOncology reviews2018
The radiation therapy options of intracranial hemangiopericytoma: An overview and update on a rare vascular mesenchymal tumor.
Article in Oncology reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Survival and prognostic factors of anaplastic hemangiopericytoma/solitary fibrous tumor grade III.Acta neurochirurgica · 2026Article
- Unveiling Hemangiopericytoma:Sultan Qaboos University medical journal · 2025Article
- The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors : A Turkish Society for Radiation Oncology Central Nervous System Tumors Group Study (TROD 07-008).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- An Invasive Solitary Fibrous Tumor/Hemangiopericytoma Originating From the Falx: A Case Report.Cureus · 2024Article
- Chronic management and recurrent challenges: a case of multifocal spinal hemangiopericytoma over 7 years. Illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- A Hemangiopericytoma in the External Auditory Canal: A Rare Clinical Presentation and Management.Cureus · 2024Article
- Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances.Brain sciences · 2022Article
- Intracranial Solitary Fibrous Tumor: A "New" Challenge for PET Radiopharmaceuticals.Journal of clinical medicine · 2022Review
- The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11).Cancer research and treatment · 2022Article
- Solitary Fibrous Tumor Revealed by Worsening Clinical Depression: A Case Report from Oman.Cureus · 2020Article
- Combined Surgical Approach to Intracranial and Extracranial Hemangiopericytoma: Case Report and Literature Review.Cureus · 2020Article
- Hemangiopericytoma/Solitary Fibrous Tumor of the Parietal Bone: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemangiopericytoma (HPC) is an extremely rare hypervascular tumor of mesenchymal lineage. It tends to recur and to develop distant metastases even many years after primary surgical resection. The management of recurrent and metastatic disease is not always so well defined. A complete surgical resection does not eliminate the high risk of local recurrences that occur in the central nervous system, often in the same surgical bed. However, treatment with adjuvant radiotherapy even in cases of complete resection remains controversial. Because of its rarity, there is no standard for treatment. We focused on radiotherapy treatment options, analyzing the literature and making a base on conduct further studies to establish the standard radiation dose to be used for locoregional control of such a complex and extremely rare disease and to help specialists to take the most appropriate therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.